Literature DB >> 6254636

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.

R W Brockman, Y C Cheng, F M Schabel, J A Montgomery.   

Abstract

The 2-fluoro derivative of 9-beta-D-arabinofuranosyladenine (2-F-ara-A) and its soluble 5'-formate and 5'-phosphate derivatives were therapeutically effective against the parent leukemia L1210 (L1210/0). 2-F-ara-A and 9-beta-D-arabinofuranosyladenine 5'-formate were inactive aginst a 1-beta-D-arabinofuranosylcytosine-resistant subline (L1210/ara-C) that was deficient in deoxycytidine kinase. Deoxycytidine prevented 2-F-ara-A-induced inhibition of proliferation of L1210/0 cells in culture and alleviated 2-F-ara-a inhibition of DNA synthesis. After treatment of mice with 9-beta-D-arabinofuranosyladenine 5'-formate, intracellular levels of the 5'-triphosphate of 9-beta-D-arabinofuranosylfluoroadenine in leukemia cells were more than 10 times higher in L1210/0 cells than in L1210/ara-C cells. Similar results were obtained in this line of leukemia cells from mice treated with the 5'-monophosphate of 9-beta-D-arabinofuranosyl-2-fluoroadenine. Thus, L1210/ara-C cells deficient in deoxycytidine kinase activity were also deficient in capacity to phosphorylate 2-F-ara-A. Kinase activity from L1210/0 cells for deoxycytidine and for 2-F-ara-A coeluted from calcium phosphate cellulose and from diethylaminoethyl cellulose columns and had similar mobility on gel electrophoresis. Deoxyadenosine kinase was clearly separated from deoxycytidine kinase. Deoxycytidine competed with 2-F-ara-A for phosphorylation by the partially purified enzyme from L1210 cells. These results indicate that 2-F-ara-A is phosphorylated to the 5'-monophosphate by deoxycytidine kinase of leukemia L1210 cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254636

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.

Authors:  Liusheng Huang; Patricia Lizak; Francesca Aweeka; Janel Long-Boyle
Journal:  J Pharm Biomed Anal       Date:  2013-08-23       Impact factor: 3.935

2.  Pharmacokinetic study of fludarabine phosphate (NSC 312887).

Authors:  M R Hersh; J G Kuhn; J L Phillips; G Clark; T M Ludden; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 4.  Membrane transport and the antineoplastic action of nucleoside analogues.

Authors:  F M Sirotnak; J R Barrueco
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 5.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

8.  Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.

Authors:  V Gandhi; L E Robertson; M J Keating; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Phase I clinical trial of fludarabine phosphate (F-ara-AMP).

Authors:  E S Casper; A Mittelman; D Kelson; C W Young
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.

Authors:  D A Carson; D B Wasson; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.